Amylyx Pharmaceuticals (AMLX) Competitors $13.98 +0.10 (+0.75%) As of 12:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMLX vs. ARWR, ACAD, ADMA, AAPG, MTSR, MIRM, ZLAB, PTGX, LNTH, and AKROShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), Metsera (MTSR), Mirum Pharmaceuticals (MIRM), Zai Lab (ZLAB), Protagonist Therapeutics (PTGX), Lantheus (LNTH), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. Its Competitors Arrowhead Pharmaceuticals ACADIA Pharmaceuticals ADMA Biologics Ascentage Pharma Group International Metsera Mirum Pharmaceuticals Zai Lab Protagonist Therapeutics Lantheus Akero Therapeutics Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk. Do analysts prefer ARWR or AMLX? Arrowhead Pharmaceuticals currently has a consensus target price of $43.14, suggesting a potential upside of 32.42%. Amylyx Pharmaceuticals has a consensus target price of $14.50, suggesting a potential upside of 3.69%. Given Arrowhead Pharmaceuticals' higher possible upside, research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, ARWR or AMLX? Amylyx Pharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$3.55M1,268.88-$599.49M-$1.28-25.45Amylyx Pharmaceuticals$87.37M14.27-$301.74M-$2.50-5.59 Which has more volatility and risk, ARWR or AMLX? Arrowhead Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Amylyx Pharmaceuticals has a beta of -0.44, indicating that its stock price is 144% less volatile than the S&P 500. Do institutionals & insiders hold more shares of ARWR or AMLX? 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to ARWR or AMLX? In the previous week, Arrowhead Pharmaceuticals and Arrowhead Pharmaceuticals both had 4 articles in the media. Amylyx Pharmaceuticals' average media sentiment score of 0.78 beat Arrowhead Pharmaceuticals' score of 0.54 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ARWR or AMLX more profitable? Arrowhead Pharmaceuticals' return on equity of -40.91% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -40.91% -11.62% Amylyx Pharmaceuticals N/A -82.48%-70.15% SummaryAmylyx Pharmaceuticals beats Arrowhead Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.25B$2.51B$5.65B$10.32BDividend YieldN/A56.32%5.68%4.61%P/E Ratio-5.6223.2775.6626.31Price / Sales14.27570.93521.00169.30Price / CashN/A174.1537.5661.52Price / Book5.835.1712.996.34Net Income-$301.74M$32.95M$3.29B$270.94M7 Day Performance5.54%0.77%-0.03%0.29%1 Month Performance64.52%5.77%4.13%6.89%1 Year Performance348.21%1.81%69.08%29.31% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals1.405 of 5 stars$13.98+0.7%$14.50+3.7%+361.1%$1.25B$87.37M-5.62200ARWRArrowhead Pharmaceuticals4.1476 of 5 stars$28.67-3.5%$43.14+50.5%+63.0%$4.11B$3.55M-22.40400ACADACADIA Pharmaceuticals4.3612 of 5 stars$24.67+4.5%$29.65+20.2%+34.2%$3.98B$957.80M18.55510Trending NewsAnalyst ForecastOptions VolumeADMAADMA Biologics3.2954 of 5 stars$15.30-5.0%$27.67+80.8%-18.8%$3.84B$426.45M17.79530AAPGAscentage Pharma Group InternationalN/A$38.63-4.5%N/AN/A$3.77B$134.35M0.00600Gap UpMTSRMetseraN/A$34.21-4.1%$63.50+85.6%N/A$3.75BN/A0.0081Analyst DowngradeMIRMMirum Pharmaceuticals3.4324 of 5 stars$74.19-0.2%$74.44+0.3%+90.5%$3.73B$336.89M0.00140Analyst ForecastZLABZai Lab3.1292 of 5 stars$31.92-2.7%$56.35+76.5%+50.6%$3.67B$398.99M-15.651,869Positive NewsPTGXProtagonist Therapeutics1.7546 of 5 stars$58.38-0.8%$67.73+16.0%+41.6%$3.66B$434.43M83.40120Insider TradeLNTHLantheus4.5336 of 5 stars$51.74-2.3%$89.67+73.3%-52.4%$3.60B$1.53B13.76700Trending NewsAKROAkero Therapeutics3.9907 of 5 stars$42.85-1.4%$81.14+89.4%+69.2%$3.48BN/A0.0030Positive News Related Companies and Tools Related Companies Arrowhead Pharmaceuticals Competitors ACADIA Pharmaceuticals Competitors ADMA Biologics Competitors Ascentage Pharma Group International Competitors Metsera Competitors Mirum Pharmaceuticals Competitors Zai Lab Competitors Protagonist Therapeutics Competitors Lantheus Competitors Akero Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMLX) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
